1 40 1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1006/mgme.1999.2815" target="_blank" rel="noreferrer noopener">http://doi.org/​10.1006/mgme.1999.2815</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Melatonin ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms recorded by wrist actigraphy Publisher An entity responsible for making the resource available Molecular Genetics and Metabolism Date A point or period of time associated with an event in the lifecycle of the resource 1999 Subject The topic of the resource Adolescent; Adult; Antioxidants/tu [Therapeutic Use]; Child; Circadian Rhythm; Dose-Response Relationship; Drug Electrophysiology; Female; Humans; Male; Melatonin/tu [Therapeutic Use]; Neuronal Ceroid-Lipofuscinoses/dt [Drug Therapy]; Sleep Wake Disorders/th [Therapy]; 0 (Antioxidants); JL5DK93RCL (Melatonin); sleep disturbance/disorders; NCL3; pharmacologic intervention; melatonin Creator An entity primarily responsible for making the resource Hätönen T; Kirveskari E; Heiskala H; Sainio K; Laakso M L; Santavuori P Description An account of the resource Melatonin was tested as a sleeping pill in five patients with neuronal ceroid lipofuscinoses. The single-blind, placebo-controlled study consisted of motor activity recordings, sleep logs, and administration of placebo or melatonin (2.5 or 5 mg). Daily motor activity rhythms were measured by wrist actigraphy during four 7-day periods (baseline, placebo, melatonin 2.5 mg, and melatonin 5 mg). The placebo or melatonin was administered in the evenings for 3 weeks, and the recordings were made during the last week of the 3-week treatment. Sleep logs were kept by the caregivers during the recordings. Based on period analyses, the activity recordings were evaluated to display a normal (24-h) or fragmented rhythm. Three patients had normal motor activity patterns during the baseline recordings, and administration of placebo or melatonin did not affect their rest/activity rhythms. Two patients had abnormally fragmented activity rhythms during the baseline periods, and administration of placebo or melatonin did not induce synchronization. According to the actigraphic data, there were no changes in activity rhythms resulting from administration of melatonin. However, based on the observations, three families reported that melatonin slightly improved the sleep quality of the patients. These controversial findings show the difficulties involved in specifying the role of melatonin in modulating sleep. Thus, we conclude that more evidence is required before the significance of melatonin as a sleeping pill is defined.Copyright 1999 Academic Press. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1006/mgme.1999.2815" target="_blank" rel="noreferrer noopener">10.1006/mgme.1999.2815</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). 0 (Antioxidants) 1999 Adolescent Adult Antioxidants/tu [Therapeutic Use] Child Circadian Rhythm Dose-Response Relationship Drug Electrophysiology Female Hätönen T Heiskala H Humans JL5DK93RCL (Melatonin) Kirveskari E Laakso M L Male melatonin Melatonin/tu [Therapeutic Use] Molecular Genetics and Metabolism NCL3 Neuronal Ceroid-Lipofuscinoses/dt [Drug Therapy] pharmacologic intervention Sainio K Santavuori P sleep disturbance/disorders Sleep Wake Disorders/th [Therapy]